Mega Genomics Balance Sheet Health
Financial Health criteria checks 5/6
Mega Genomics has a total shareholder equity of CN¥644.8M and total debt of CN¥22.6M, which brings its debt-to-equity ratio to 3.5%. Its total assets and total liabilities are CN¥796.5M and CN¥151.7M respectively. Mega Genomics's EBIT is CN¥26.3M making its interest coverage ratio -5.3. It has cash and short-term investments of CN¥526.3M.
Key information
3.5%
Debt to equity ratio
CN¥22.64m
Debt
Interest coverage ratio | -5.3x |
Cash | CN¥526.27m |
Equity | CN¥644.83m |
Total liabilities | CN¥151.72m |
Total assets | CN¥796.54m |
Recent financial health updates
No updates
Recent updates
Some Investors May Be Worried About Mega Genomics' (HKG:6667) Returns On Capital
May 03Calculating The Intrinsic Value Of Mega Genomics Limited (HKG:6667)
Feb 20Mega Genomics Limited's (HKG:6667) Share Price Could Signal Some Risk
Aug 12A Look At The Fair Value Of Mega Genomics Limited (HKG:6667)
Nov 07Financial Position Analysis
Short Term Liabilities: 6667's short term assets (CN¥667.8M) exceed its short term liabilities (CN¥114.3M).
Long Term Liabilities: 6667's short term assets (CN¥667.8M) exceed its long term liabilities (CN¥37.4M).
Debt to Equity History and Analysis
Debt Level: 6667 has more cash than its total debt.
Reducing Debt: Insufficient data to determine if 6667's debt to equity ratio has reduced over the past 5 years.
Debt Coverage: 6667's debt is well covered by operating cash flow (723.1%).
Interest Coverage: 6667 earns more interest than it pays, so coverage of interest payments is not a concern.